Journal of Cardiac Failure最新文献

{"title":"Underpinnings of Heart Failure With Preserved Ejection Fraction in Women - From Prevention to Improving Function. A Co-publication With the American Journal of Preventive Cardiology and the Journal of Cardiac Failure","authors":"ANKITHA RADAKRISHNAN ,&nbsp;SALONI AGRAWAL ,&nbsp;NAUSHEEN SINGH ,&nbsp;ANNA BARBIERI ,&nbsp;LESLEE J. SHAW ,&nbsp;MARTHA GULATI ,&nbsp;ANURADHA LALA","doi":"10.1016/j.cardfail.2025.01.008","DOIUrl":"10.1016/j.cardfail.2025.01.008","url":null,"abstract":"<div><div>Heart failure with preserved ejection fraction (HFpEF) represents a major clinical challenge with rising global prevalence. Women have a nearly double lifetime risk of developing HFpEF compared to heart failure with reduced ejection fraction (HFrEF). In HFpEF, sex differences emerge both in how traditional cardiovascular risk factors (such as hypertension, obesity, and diabetes) affect cardiac function and through distinct pathophysiological mechanisms triggered by sex-specific events like menopause and adverse pregnancy outcomes. These patterns influence not only disease development, but also therapeutic responses, necessitating sex-specific approaches to treatment. This review aims to synthesize existing knowledge regarding HFpEF in women including traditional and sex-specific risk factors, pathophysiology, presentation, and therapies, while outlining important knowledge gaps that warrant further investigation. The impact of HFpEF spans a woman's entire lifespan, requiring prevention and management strategies tailored to different life stages. While understanding of sex-based differences in HFpEF has improved, significant knowledge gaps persist. Through examination of current evidence and challenges, this review highlights promising opportunities for innovative research, therapeutic development, and clinical care approaches that could transform the management of HFpEF in women.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 9","pages":"Pages 1460-1475"},"PeriodicalIF":8.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitators and Barriers to Values Discussions Following LVAD Implantation: Perspectives from Diverse Patients and Family Caregivers","authors":"AVERY C. BECHTHOLD PhD, BSN, RN ,&nbsp;DEBORAH B. EJEM PhD ,&nbsp;COLLEEN K. MCILVENNAN PhD, DNP, ANP ,&nbsp;DANIEL D. MATLOCK MD, MPH ,&nbsp;CHRISTOPHER E. KNOEPKE PhD, MSW ,&nbsp;JESSE LEJEUNE CRNP ,&nbsp;MARIE A. BAKITAS DNSc, NP-C, FAAN ,&nbsp;J. NICHOLAS ODOM PhD, RN","doi":"10.1016/j.cardfail.2024.11.015","DOIUrl":"10.1016/j.cardfail.2024.11.015","url":null,"abstract":"<div><h3>Background</h3><div>Delivering care that is responsive to who or what is most important to patients and family caregivers is a key aspect of quality care, yet it remains unclear how clinicians can best support individuals in expressing their personal values. We aimed to describe patient- and family caregiver–identified facilitators and barriers to engaging in values discussions with clinicians following implantation of a left ventricular assist device (LVAD).</div></div><div><h3>Methods and results</h3><div>Using a qualitative descriptive approach, patients with an LVAD and their caregivers participated in 1-on-1 semistructured interviews and self-reported sociodemographics (January 2023–July 2023). Qualitative data were analyzed using thematic analysis and descriptive statistics were computed for quantitative data.</div></div><div><h3>Results</h3><div>Patients (n = 27; ages 30–76 years) were predominantly male (59%) and non-Hispanic Black (67%). Caregivers (n = 21; ages 27–76) were female (76%), non-Hispanic Black (67%), and a spouse/partner (62%). Facilitators (5 shared across patient/caregiver groups; 8 unique across patient/caregiver groups) included a perceived close relationship (patient/caregiver), values alignment (patient/caregiver), clinician discussion initiation (patient/caregiver), facing an impending decision (patient/caregiver), 1-on-1 dyadic interactions (patient/caregiver), being assertive (patient), positive dyadic communication (caregiver), and involvement of a third party (caregiver). Barriers (2 shared; 7 unique) included belief that their values are already known (patient/caregiver), sensitivity about values (patient/caregiver), uncertainty about timing (patient), poor clinical communication (patient), patient hopelessness (patient), perceived lack of clinician time (caregiver), and having a reserved personality (caregiver).</div></div><div><h3>Conclusion</h3><div>Findings offer insight into actionable facilitators and barriers to discussions promoting incorporation of patient and family values into LVAD maintenance and chronic disease management.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 9","pages":"Pages 1393-1404"},"PeriodicalIF":8.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital-Level Variation and Predictive Model for Diagnosis of Transthyretin Amyloid Cardiomyopathy Among Patients Hospitalized Due to Heart Failure","authors":"SATOSHI SHOJI MD, PhD ,&nbsp;NICOLE SOLOMON PhD ,&nbsp;KAREN CHISWELL PhD ,&nbsp;SENTHIL SELVARAJ MD, MS, MA ,&nbsp;MICHEL G. KHOURI MD ,&nbsp;SABRA C. LEWSEY MD, MPH ,&nbsp;LORI BAYLOR PhD ,&nbsp;MARIANNA BRUNO PharmD, MPH ,&nbsp;GREGG C. FONAROW MD ,&nbsp;STEPHEN J. GREENE MD","doi":"10.1016/j.cardfail.2025.03.013","DOIUrl":"10.1016/j.cardfail.2025.03.013","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 9","pages":"Pages 1480-1485"},"PeriodicalIF":8.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Survival Outcomes With Cardiac Contractility Modulation: Methodological Validation Using Cardiac Resynchronization Therapy Data","authors":"ANDREW J. SAUER MD ,&nbsp;RYAN HASS ,&nbsp;GARY CRANKE ,&nbsp;DANIEL BURKHOFF MD ,&nbsp;ISHU RAO MD","doi":"10.1016/j.cardfail.2025.04.013","DOIUrl":"10.1016/j.cardfail.2025.04.013","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 9","pages":"Pages 1490-1492"},"PeriodicalIF":8.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting Myocardial Recovery in Anthracycline Cardiomyopathy: Defining the Steps to Success in Contemporary Practice","authors":"MICHAEL C. HILL M.D., M.S., ,&nbsp;JOSHUA A. JACOBS Pharm.D., Ph.D. ,&nbsp;JANE E. WILCOX M.D., M.Sc.","doi":"10.1016/j.cardfail.2025.07.003","DOIUrl":"10.1016/j.cardfail.2025.07.003","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 9","pages":"Pages 1390-1392"},"PeriodicalIF":8.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Paradigms and Future Frontiers in Heart Transplantation in the Modern Era: a State-of-Art Focus Review.","authors":"Ameesh Isath, Milica Vukićević, Roxana Moayedifar, Andreas Zuckermann, Mandeep R Mehra","doi":"10.1016/j.cardfail.2025.07.016","DOIUrl":"10.1016/j.cardfail.2025.07.016","url":null,"abstract":"<p><p>Heart transplantation stands at the threshold of a new era shaped by transformative advances across the clinical and scientific continuum. This contemporary review highlights developments with the greatest potential to shift practice and improve patients' outcomes. First, evolving strategies in organ preservation and transport, such as ex situ perfusion and normothermic techniques, are expanding geographic boundaries and optimizing donor-heart use. Second, the complex decision-making calculus between heart transplantation and durable left ventricular assist device (LVAD) implantation hinges increasingly on individualized assessments of net survival benefit. Third, the donor pool is being meaningfully expanded through the successful incorporation of hearts from donation after circulatory death (DCD) and hepatitis C virus (HCV)-positive donors, marking a paradigm shift in organ availability. Fourth, the field is witnessing a move toward precision immunosuppression, guided by novel noninvasive biomarkers and surveillance technologies that promise earlier detection of rejection and better immunological control. Fifth, as survival rates improve, attention is turning to the long arc of posttransplant care, addressing late complications, such as cardiac allograft vasculopathy, malignancy, and renal dysfunction, with greater therapeutic insight. Finally, pioneering advances in xenotransplantation signal a bold frontier, with early scientific successes rekindling hopes for overcoming the perennial challenge of organ shortage. Together, these innovations underscore a dynamic and rapidly evolving landscape in heart transplantation-a landscape that demands both clinical adaptability and continued scientific rigor.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amyloid-Specific Medication in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Cardiovascular Outcome trials.","authors":"Maximilian Autherith, Laurenz Hauptmann, Sophia Koschatko, Charlotte Jantsch, Christina Kronberger, Michael Poledniczek, Kseniya Halavina, Caglayan Demirel, Robin Ristl, Franz Duca, Andreas Kammerlander, Mazen Hanna, Marianna Fontana, Mathew Maurer, Philipp E Bartko, Christian Nitsche","doi":"10.1016/j.cardfail.2025.08.002","DOIUrl":"10.1016/j.cardfail.2025.08.002","url":null,"abstract":"<p><strong>Background: </strong>The introduction of disease-specific medication has revolutionized the management of transthyretin-associated cardiomyopathy (ATTR-CM). However, dedicated trials included different patient populations, primary endpoints, and follow-up periods, rendering study comparison challenging. This systematic review and meta-analysis aimed to harmonize data from all phase 3 placebo-controlled drug trials in ATTR-CM to elucidate the magnitude and timing of treatment efficacy of ATTR-specific medication.</p><p><strong>Methods: </strong>We searched PubMed and Embase for trials published up to February 23, 2025 (PROSPERO: CRD42025645376). Efficacy outcomes included all-cause death, cardiovascular (CV) events, change in 6-minute walk distance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and Kansas City Cardiomyopathy Questionnaire Overall Score. Outcome metrics were pooled across trials using inverse-variance weighting and a random-effects model.</p><p><strong>Results: </strong>We included data from 4 identified trials (ATTR-ACT, ATTRibute, APOLLO-B, and HELIOS-B) and 2086 patients. Baseline risk profiles differed substantially, highlighted by a decrease in NT-proBNP and estimated glomerular filtration rate levels from earlier to later trials, likely resulting in different death rates of the respective placebo groups. At 12 months, ATTR-specific medication showed a trend toward less decline in 6-minute walk distance (least squares mean difference: 12.9 meters; 95% confidence interval [CI] -4.1 to 29.8) and was associated with a significantly blunted decline in Kansas City Cardiomyopathy Questionnaire Overall Score (least squares mean difference: 4.7 points; 95% CI 2.3-7.0) and NT-proBNP (geometric mean fold ratio 0.80; 95% CI 0.74-0.85) compared with placebo. These effects are consolidated with continued treatment. At 12-months, ATTR-specific medication did not improve all-cause mortality (OR 1.00; 95% CI 0.69-1.44) compared with placebo. Conversely, over the maximum follow-up period and at 30 months, respectively, ATTR-specific medication reduced the risk of all-cause mortality by 28% (HR 0.72; 95% CI 0.59-0.87) and for CV events by 42% (OR 0.58; 95%CI 0.47-0.73).</p><p><strong>Conclusions: </strong>ATTR-specific medication exhibits early salutary effects on blood biomarkers, functional capacity and quality of life. These effects translate into reductions in CV events and all-cause mortality after continued treatment.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America.","authors":"","doi":"10.1016/j.cardfail.2025.07.007","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.07.007","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.","authors":"Christopher M O'Connor, Sarah Rathwell, Devan V Mehrotra, Stefano Corda, Ciaran J McMULLAN, Carolyn S P Lam, Justin A Ezekowitz, Burkert Piekse, Adrian F Hernandez, Kevin J Anstrom, Robert J Mentz, Christopher R Defilippi, Adriaan Voors, Piotr Ponikowski, Javed Butler, Cynthia M Westerhout, Paul W Armstrong","doi":"10.1016/j.cardfail.2025.07.024","DOIUrl":"10.1016/j.cardfail.2025.07.024","url":null,"abstract":"<p><strong>Background: </strong>Randomized trials remain the standard for evaluating novel therapies. Primary endpoint(s) risk heterogeneity and may dilute treatment efficacy. The 5-step Stratified Testing and Amalgamation Routine (5-STAR) methodology helps to address these limitations. We applied this methodology to the original VICTORIA (VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) database and enriched it by relevant ancillary information.</p><p><strong>Methods: </strong>Elastic net Cox regression and a conditional inference-tree tool blinded to treatment assignment partitioned the population into risk strata for endpoints based on baseline covariates strongly associated with outcomes. Core laboratory biomarkers and baseline electrocardiographic variables were available covariates. After unblinding, treatments were compared for the primary composite endpoint of cardiovascular death or heart failure hospitalization (HFH) within each risk stratum: stratum-level results were averaged for overall inference.</p><p><strong>Results: </strong>The 5-STAR analysis revealed greater vericiguat efficacy pooled on the primary composite endpoint than the original VICTORIA analysis (5-STAR HR, 95% CI: 0.85, 0.77-0.94 vs 0.90, 0.82-0.98), and its components (5-STAR HR, 95% CI: cardiovascular death: 0.79, 0.67-0.93 vs 0.93, 0.81-1.06; HFH: 0.89, 0.79-1.00 vs 0.90, 0.81-1.00). Five biomarkers (GDF-15, NT-proBNP, albumin, blood urea nitrogen, and uric acid) determined the risk strata across the 3 endpoints.</p><p><strong>Conclusions: </strong>The 5-STAR methodology attenuates the dilution of treatment effects inherent in conventional prognostic risk heterogeneity. This retrospective analysis of VICTORIA revealed greater efficacy of vericiguat on the primary endpoint and its components. GDF-15 was consistently the strongest prognostic risk factor across the composite endpoint and its components.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Not Lost in Translation: Learning From the Non-native English-Speaking Heart Transplant Recipient Experience.","authors":"Thomas M Cascino, Geoffrey D Barnes","doi":"10.1016/j.cardfail.2025.08.005","DOIUrl":"10.1016/j.cardfail.2025.08.005","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}